echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Within a week, the pharmaceutical company has received research from more than 340 institutions

    Within a week, the pharmaceutical company has received research from more than 340 institutions

    • Last Update: 2022-01-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    From January 5 to January 11, about 171 listed companies in Shanghai and Shenzhen were investigated by the agency
    .
    In the institutional survey list, a total of 45 companies have been surveyed by more than 20 institutions
    .
    On the whole, the mechanical equipment, electronics and medical biology sectors
    .
    Among them, there are 21 pharmaceutical and biological enterprises, and more than 460 institutions have received research
    .
    It is worth mentioning that among the 21 pharmaceutical companies, Huadong Medicine has attracted a lot of attention, and more than 340 institutions have participated in the survey; followed by Xianju Pharmaceutical and Teyi Pharmaceutical
    .
    Specifically, on January 6, Huadong Medicine released a record form of investor relations activities.
    The announcement showed that on January 5, more than 280 institutional and individual investors including Goldman Sachs Group, Gao Yi Assets, BlackRock and Sequoia Capital A total of 525 people attended Huadong Medicine's online meeting
    .
    In the interactive exchanges with investors, the institution expressed concern about the company's industrial microbe product layout, CMO and CDMO business situation, the company's views on the future competition in the domestic industrial microbe field, and plans for industrial microbe R&D investment
    .
    Then on the 10th, Huadong Medicine issued another announcement saying: Huatai Pineapple, Toroa Management, Industrial Securities, Bank of Communications Schroders Fund, Ping An Asset, GF Fund, Nanhua Fund, Huisheng Fund, BlackRock Fund, Sequoia Capital , Guotai Junan Asset Management, Jiahe Fund, Minsheng Jiayin Fund, Qianhai United Fund, Guolian Fund, Taikang Assets and other 40 institutions investigated our company on January 7, 2022
    .
    The main contents of this investigation include key strategic layout directions, clinical results of some innovative drugs, and progress of liraglutide products
    .
    It is worth mentioning that a large number of enterprises also participated in the survey on the 10th
    .
    Including Hongze Research, Zhongtian Guofu Securities, Everbright Prudential Fund, Huaan Fund, Nufus Investment, Wangzheng Asset, Rushan Jianying Asset, Botong Investment, Freshwater Spring Investment, Fu Pei Investment, Xinghe Fund, Pengwan Fund , Bohong Asset, Chengsheng Investment and other 53 institutions
    .
    On January 5, 2022, Teyi Pharmaceutical issued an announcement saying: Huaan Securities Tan Guochao Li Changxing, Huaan Securities Research Institute Huang Jing, Xihong Private Equity Fund Yang Ying, Neoan Fund Zeng Guangkun, Capule Tang Han on January 5, 2022 Investigate our company every day
    .
    On the whole, the main content of the research of many institutions is on the cough medicine tablets
    .
    Subsequently, on January 10, Teyi Pharmaceutical issued an announcement stating that Zheshang Securities, Founder Self-operated, Southern Asset Management, Harvest Fund, Taiping Asset Fu Tao, SDIC UBS, Da Da Asset, Boyuan Fund, China Post 22 institutions including the Fund and Dacheng Fund also visited the company on January 10, 2022
    .
    The main contents of the survey include the progress of the company's NMN project, the impact of the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine" on the company, the company's revenue structure, and the proportion of sales revenue from various drugs
    .
    On January 6, 2022, Xianju Pharmaceutical also released a record of investor relations activities
    .
    The announcement shows that on January 5, 2022, the company was surveyed by 63 institutional units, and the types of institutions were insurance companies, others, fund companies, securities companies, and sunshine private equity institutions
    .
    In the survey, investors are more concerned about the medium and long-term strategic positioning of Xianju Pharmaceutical
    .
    In this regard, Xianju Pharmaceutical stated that the company will focus on the field of steroid hormones for a long time, complete and refine the hormone industry chain, continuously enrich the product structure of APIs and preparations, and focus on the improvement of comprehensive capabilities
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.